



**Pediatric Central IRB Meeting Agenda**  
**Thursday, January 12, 2017**  
**11:00 am – 12:40 pm Eastern Time**

**Agenda**

---

**I. General Business**

- **Next Meetings:** Friday, January 20, 2017  
Thursday, February 9, 2017
  - **CIRB Member Assessment Process**
- 

**II. Reports for 12/01/16 – 12/31/16**

- Pediatric CIRB Local Context Subcommittee Report
  - Expedited Reviews and Study Acknowledgements
  - Study Activation Acknowledgements
  - Amendment Activation Acknowledgements
- 

**III. Review/Approval of Minutes**

- December 8, 2016
- 

**IV. Continuing Review**

**ARST1431**, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (Protocol Version Date 03/22/16)

---

**V. Continuing Review**

**ACCL1034**, Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT): A Limited Phase III Study (Protocol Version Date 09/24/14)

---

**VI. Initial Review**

**APEC1621**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Study (Protocol Version Date 12/27/16)

---